UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Should HIV therapy be started at a CD4 cell count above 350 cells/mu l in asymptomatic HIV-1-infected patients?

Sabin, CA; Phillips, AN; (2009) Should HIV therapy be started at a CD4 cell count above 350 cells/mu l in asymptomatic HIV-1-infected patients? CURR OPIN INFECT DIS , 22 (2) 191 - 197. 10.1097/QCO.0b013e328326cd34.

Full text not available from this repository.

Abstract

Purpose of reviewThe aim is to review the available data that contribute to the debate on the optimal time to initiate highly active antiretroviral therapy (HAART) in HIV-infected individuals with a CD4 cell count more than 350 cells/mu l.Recent findingsAlthough few randomized data exist that can contribute to this debate, a number of findings from observational studies generally support earlier initiation of HAART. In particular, the findings that death rates remain higher in HIV-infected individuals than in uninfected individuals, even when successfully treated, and that both AIDS and several serious non-AIDS events are more common in those with a lower CD4 cell count (even when this count is above 350 cells/mu l), suggest that earlier initiation of HAART may prevent much of the excess morbidity and mortality that remains in this patient group.SummaryCurrently, the data would generally support initiation of HAART in patients with CD4 cell counts more than 350 cells/mu l. However, given the strong potential for confounding in observational studies and the lack of adjustment for lead-time bias in many analyses, it is not possible to rule out possible long-term detrimental effects of earlier use of HAART until the results from fully powered randomized trials that directly address this issue become available.

Type: Article
Title: Should HIV therapy be started at a CD4 cell count above 350 cells/mu l in asymptomatic HIV-1-infected patients?
DOI: 10.1097/QCO.0b013e328326cd34
Keywords: antiretroviral therapy, CD4 cell count, HIV infection, when to start treatment, ACTIVE ANTIRETROVIRAL THERAPY, HUMAN-IMMUNODEFICIENCY-VIRUS, SHORT-TERM RISK, INFECTED PATIENTS, BASE-LINE, VIROLOGICAL SUPPRESSION, OBSERVATIONAL COHORT, VIRAL LOAD, CARDIOVASCULAR-DISEASE, CLINICAL PROGRESSION
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health > Infection and Population Health
URI: http://discovery.ucl.ac.uk/id/eprint/118308
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item